5月7日,国(guo)(guo)(guo)药(yao)集(ji)团(tuan)中国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)北京生(sheng)(sheng)物(wu)(wu)制(zhi)品(pin)(pin)研究所研制(zhi)的新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)获(huo)得世界卫生(sheng)(sheng)组(zu)(zu)织紧急使用认证,是第一个获(huo)世卫组(zu)(zu)织批(pi)准的中国(guo)(guo)(guo)新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)。6月1日,国(guo)(guo)(guo)药(yao)集(ji)团(tuan)中国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)北京生(sheng)(sheng)物(wu)(wu)制(zhi)品(pin)(pin)研究所首批(pi)供应(ying)世卫组(zu)(zu)织“新(xin)冠(guan)(guan)(guan)肺(fei)炎(yan)疫(yi)苗(miao)实(shi)施计划”(COVAX)的新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)下(xia)线,这(zhei)也(ye)是首批(pi)供应(ying)COVAX的中国(guo)(guo)(guo)新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)。目(mu)(mu)前(qian)(qian),国(guo)(guo)(guo)药(yao)集(ji)团(tuan)生(sheng)(sheng)产的新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)已(yi)在全(quan)球80余(yu)个国(guo)(guo)(guo)家(jia)和(he)(he)国(guo)(guo)(guo)际组(zu)(zu)织获(huo)批(pi)注册上市或紧急使用,已(yi)供应(ying)130多个国(guo)(guo)(guo)家(jia)和(he)(he)地(di)区,接种人群覆盖196个国(guo)(guo)(guo)别。国(guo)(guo)(guo)药(yao)集(ji)团(tuan)中国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)是目(mu)(mu)前(qian)(qian)全(quan)球唯一一家(jia)独立自(zi)主在2条技术路线上研发出3款新(xin)冠(guan)(guan)(guan)疫(yi)苗(miao)的企业。这(zhei)是中国(guo)(guo)(guo)新(xin)冠(guan)(guan)(guan)病(bing)(bing)毒(du)疫(yi)苗(miao)作为全(quan)球公共产品(pin)(pin)的生(sheng)(sheng)动(dong)实(shi)践,为实(shi)现疫(yi)苗(miao)可及性和(he)(he)可负担性贡(gong)献了力量。
科技(ji)自(zi)立自(zi)强 破(po)解技(ji)术(shu)难(nan)题
新(xin)冠肺炎疫(yi)情(qing)发(fa)(fa)(fa)生(sheng)后,国(guo)(guo)药集(ji)(ji)团党(dang)委号召集(ji)(ji)团上(shang)下全(quan)(quan)员动员、全(quan)(quan)线(xian)(xian)出(chu)击(ji)、全(quan)(quan)域作战、全(quan)(quan)力(li)以赴,全(quan)(quan)力(li)推进(jin)新(xin)冠疫(yi)苗(miao)(miao)研(yan)制工作。2020年1月,国(guo)(guo)药集(ji)(ji)团对疫(yi)苗(miao)(miao)研(yan)发(fa)(fa)(fa)作出(chu)部(bu)署,2月1日获(huo)科(ke)技(ji)部(bu)紧急立(li)项后,国(guo)(guo)药集(ji)(ji)团中国(guo)(guo)生(sheng)物迅速组建(jian)多个(ge)科(ke)研(yan)团队(dui)同(tong)步研(yan)发(fa)(fa)(fa),在(zai)诊断、治疗、预防三条战线(xian)(xian)全(quan)(quan)力(li)开展抗疫(yi)科(ke)技(ji)攻关,研(yan)发(fa)(fa)(fa)出(chu)核酸分(fen)子(zi)检测(ce)试(shi)剂;提出(chu)康复者(zhe)恢复期血(xue)浆治疗技(ji)术并(bing)研(yan)发(fa)(fa)(fa)出(chu)新(xin)冠特异性免疫(yi)球蛋白;研(yan)发(fa)(fa)(fa)出(chu)全(quan)(quan)球首个(ge)新(xin)冠灭活疫(yi)苗(miao)(miao),为疫(yi)情(qing)防控提供有力(li)支撑(cheng)。
新(xin)冠(guan)(guan)(guan)疫(yi)(yi)(yi)苗(miao)科(ke)技(ji)攻(gong)关中(zhong)(zhong),国(guo)(guo)(guo)药(yao)(yao)集(ji)团中(zhong)(zhong)国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)独立自主破解了(le)高等级生(sheng)(sheng)物(wu)(wu)安全条(tiao)件(jian)下大规模(mo)生(sheng)(sheng)产(chan)灭(mie)活(huo)疫(yi)(yi)(yi)苗(miao)的一(yi)系列难题,攻(gong)克“卡脖子”技(ji)术,实现了(le)从(cong)千万剂(ji)级到数(shu)十亿(yi)剂(ji)级的跨越,源源不断制(zhi)造(zao)出新(xin)冠(guan)(guan)(guan)灭(mie)活(huo)疫(yi)(yi)(yi)苗(miao)支(zhi)援全球(qiu)抗(kang)疫(yi)(yi)(yi)。2020年12月(yue)30日(ri),国(guo)(guo)(guo)药(yao)(yao)集(ji)团中(zhong)(zhong)国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)北京生(sheng)(sheng)物(wu)(wu)制(zhi)品研(yan)(yan)究所(suo)新(xin)冠(guan)(guan)(guan)灭(mie)活(huo)疫(yi)(yi)(yi)苗(miao)在中(zhong)(zhong)国(guo)(guo)(guo)获批(pi)(pi)附条(tiao)件(jian)上市。2021年2月(yue)25日(ri),国(guo)(guo)(guo)药(yao)(yao)集(ji)团中(zhong)(zhong)国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)武汉(han)生(sheng)(sheng)物(wu)(wu)制(zhi)品研(yan)(yan)究所(suo)新(xin)冠(guan)(guan)(guan)灭(mie)活(huo)疫(yi)(yi)(yi)苗(miao)获批(pi)(pi)附条(tiao)件(jian)上市;4月(yue)9日(ri),国(guo)(guo)(guo)药(yao)(yao)集(ji)团中(zhong)(zhong)国(guo)(guo)(guo)生(sheng)(sheng)物(wu)(wu)技(ji)术研(yan)(yan)究院基(ji)因重组新(xin)冠(guan)(guan)(guan)疫(yi)(yi)(yi)苗(miao)获得临床试(shi)验批(pi)(pi)件(jian)。
传承百年(nian)积淀 打破常规研(yan)发
1919年,我国(guo)最(zui)早从(cong)事传染病细菌(jun)学研(yan)究和生(sheng)物制品生(sheng)产(chan)的机(ji)构——中央防疫(yi)处(chu)成立,这是国(guo)药集团中国(guo)生(sheng)物的前身(shen)。如今,国(guo)药集团中国(guo)生(sheng)物已成为亚洲产(chan)品最(zui)全、规(gui)模(mo)最(zui)大、综(zong)合(he)实(shi)力(li)最(zui)强(qiang)的生(sheng)物医药企业(ye)之一,年产(chan)疫(yi)苗(miao)(miao)50余种,在(zai)国(guo)家免疫(yi)规(gui)划全部15种疾病疫(yi)苗(miao)(miao)中,担负了(le)超过80%的供(gong)应任务,是我国(guo)生(sheng)物制品行业(ye)的领(ling)先企业(ye)。
针对此次新冠病毒疫苗(miao)(miao)研(yan)发(fa)(fa),国药集(ji)团(tuan)中国生(sheng)物敢于(yu)打破常规。一是与时间赛跑(pao),全面(mian)部署(shu)疫苗(miao)(miao)研(yan)发(fa)(fa)任务。仅98天就进入临床(chuang)(chuang)试验,177天投入紧急使用,335天正(zheng)式(shi)上市,累计投入研(yan)发(fa)(fa)、临床(chuang)(chuang)、生(sheng)产费用超过(guo)100亿元。二是从实(shi)际出发(fa)(fa),优(you)选技(ji)术(shu)攻关路线。全面(mian)布局5条(tiao)技(ji)术(shu)路线,通过(guo)认(ren)真比选论证,考虑到灭活疫苗(miao)(miao)和基因(yin)重(zhong)组疫苗(miao)(miao)技(ji)术(shu)成熟(shu)、标(biao)准(zhun)可控、保护效果好等(deng),选择主攻灭活路线,并布局北京生(sheng)物所、武汉生(sheng)物所两个研(yan)究所开(kai)展(zhan)灭活疫苗(miao)(miao)研(yan)发(fa)(fa),同时,国药中生(sheng)研(yan)究院基因(yin)重(zhong)组疫苗(miao)(miao)快(kuai)速(su)推进,均(jun)取得(de)成功。三(san)是始终(zhong)坚持(chi)科学严谨(jin)规范的(de)要求。研(yan)发(fa)(fa)团(tuan)队创造性(xing)地将流程由过(guo)去的(de)串联(lian)改为并联(lian),大大加快(kuai)研(yan)发(fa)(fa)速(su)度,在研(yan)发(fa)(fa)过(guo)程中,坚持(chi)“流程不(bu)减、标(biao)准(zhun)不(bu)变、数据不(bu)省(sheng)”原(yuan)则,制定(ding)科学规范的(de)研(yan)究方案,接受严格的(de)监(jian)管要求和专业审议。四是持(chi)续技(ji)术(shu)提升,在传统(tong)灭活疫苗(miao)(miao)技(ji)术(shu)平台上,实(shi)现多项(xiang)突破,取得(de)多个创新成果。
坚持党建(jian)引领 提升疫苗产能
为提(ti)升疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)产(chan)(chan)(chan)(chan)能,推动疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)大(da)规模使(shi)用,国(guo)药集(ji)团中(zhong)国(guo)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)克服重(zhong)重(zhong)困(kun)难,在(zai)北京生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)所(suo)(suo)58天(tian)(tian)建(jian)(jian)成(cheng)(cheng)(cheng)国(guo)内首个(ge)(ge)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian),97天(tian)(tian)、98天(tian)(tian)分别建(jian)(jian)成(cheng)(cheng)(cheng)第(di)二个(ge)(ge)、第(di)三(san)个(ge)(ge)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian);在(zai)武汉生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)所(suo)(suo),86天(tian)(tian)建(jian)(jian)成(cheng)(cheng)(cheng)第(di)一个(ge)(ge)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3实验室和P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian)综(zong)合体,76天(tian)(tian)建(jian)(jian)成(cheng)(cheng)(cheng)第(di)二个(ge)(ge)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian);目前(qian)正在(zai)长春(chun)(chun)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)所(suo)(suo)、兰州生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)所(suo)(suo)建(jian)(jian)设新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3实验室和P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian)。与此同时,64天(tian)(tian)完成(cheng)(cheng)(cheng)对国(guo)药集(ji)团所(suo)(suo)属北京、武汉、长春(chun)(chun)、兰州、成(cheng)(cheng)(cheng)都、上海6个(ge)(ge)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)制品研究所(suo)(suo)的(de)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)配套(tao)生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)基地改(gai)造建(jian)(jian)设。另外,在(zai)阿联酋(qiu)、塞(sai)尔维(wei)亚、阿根廷等国(guo)家的(de)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)灌装(zhuang)车(che)(che)间(jian)(jian)正陆续投(tou)产(chan)(chan)(chan)(chan)。6月底,随(sui)着(zhe)北京生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)所(suo)(suo)第(di)三(san)个(ge)(ge)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)P3生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)车(che)(che)间(jian)(jian)建(jian)(jian)成(cheng)(cheng)(cheng)投(tou)产(chan)(chan)(chan)(chan),国(guo)药集(ji)团中(zhong)国(guo)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)新(xin)冠(guan)(guan)病(bing)(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)整体年(nian)产(chan)(chan)(chan)(chan)能超(chao)过50亿剂(ji),成(cheng)(cheng)(cheng)为目前(qian)全球(qiu)最大(da)新(xin)冠(guan)(guan)疫(yi)(yi)(yi)苗(miao)(miao)(miao)(miao)研发(fa)生(sheng)(sheng)(sheng)(sheng)(sheng)产(chan)(chan)(chan)(chan)基地和供应商。
国药(yao)(yao)集(ji)(ji)团(tuan)党委书记、董(dong)事长刘敬桢表示,国药(yao)(yao)集(ji)(ji)团(tuan)勇担央企(qi)责(ze)任,坚(jian)持人(ren)民至上、生(sheng)(sheng)命(ming)至上,在(zai)医药(yao)(yao)物资(zi)供应保障、科研(yan)生(sheng)(sheng)产、新冠病(bing)毒(du)疫(yi)苗科技攻关和生(sheng)(sheng)产供应等各条战(zhan)线(xian)全面出击,取得一系(xi)列重(zhong)要战(zhan)略成(cheng)果,护佑了人(ren)民生(sheng)(sheng)命(ming)健康,捍卫了公(gong)共(gong)(gong)卫生(sheng)(sheng)安(an)全,未来,国药(yao)(yao)集(ji)(ji)团(tuan)将进(jin)一步发(fa)挥中国新冠病(bing)毒(du)疫(yi)苗作为(wei)全球(qiu)公(gong)共(gong)(gong)产品的重(zhong)要作用,造福国人(ren),为(wei)全球(qiu)抗疫(yi)贡献(xian)力量。
数据来源:国药集团
5月7日,国(guo)(guo)药(yao)(yao)集团(tuan)中(zhong)(zhong)国(guo)(guo)生(sheng)(sheng)物北(bei)京生(sheng)(sheng)物制品研(yan)究所(suo)研(yan)制的(de)(de)(de)(de)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)获(huo)得世(shi)界卫(wei)(wei)生(sheng)(sheng)组织紧急(ji)使(shi)用认(ren)证,是第一(yi)(yi)个(ge)获(huo)世(shi)卫(wei)(wei)组织批准的(de)(de)(de)(de)中(zhong)(zhong)国(guo)(guo)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)。6月1日,国(guo)(guo)药(yao)(yao)集团(tuan)中(zhong)(zhong)国(guo)(guo)生(sheng)(sheng)物北(bei)京生(sheng)(sheng)物制品研(yan)究所(suo)首批供(gong)应(ying)世(shi)卫(wei)(wei)组织“新(xin)(xin)(xin)冠肺炎疫(yi)(yi)(yi)苗(miao)实(shi)施计划”(COVAX)的(de)(de)(de)(de)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)下线(xian),这(zhei)也是首批供(gong)应(ying)COVAX的(de)(de)(de)(de)中(zhong)(zhong)国(guo)(guo)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)。目前,国(guo)(guo)药(yao)(yao)集团(tuan)生(sheng)(sheng)产的(de)(de)(de)(de)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)已在(zai)(zai)全球(qiu)80余个(ge)国(guo)(guo)家和国(guo)(guo)际组织获(huo)批注册上(shang)市或紧急(ji)使(shi)用,已供(gong)应(ying)130多个(ge)国(guo)(guo)家和地区,接种人(ren)群覆盖196个(ge)国(guo)(guo)别。国(guo)(guo)药(yao)(yao)集团(tuan)中(zhong)(zhong)国(guo)(guo)生(sheng)(sheng)物是目前全球(qiu)唯一(yi)(yi)一(yi)(yi)家独(du)立自主在(zai)(zai)2条技术路线(xian)上(shang)研(yan)发(fa)出3款新(xin)(xin)(xin)冠疫(yi)(yi)(yi)苗(miao)的(de)(de)(de)(de)企业。这(zhei)是中(zhong)(zhong)国(guo)(guo)新(xin)(xin)(xin)冠病(bing)(bing)毒(du)(du)疫(yi)(yi)(yi)苗(miao)作为(wei)全球(qiu)公共产品的(de)(de)(de)(de)生(sheng)(sheng)动实(shi)践,为(wei)实(shi)现疫(yi)(yi)(yi)苗(miao)可及(ji)性和可负担性贡献了力量。
科技自立自强 破解(jie)技术难题
新冠肺炎疫情发(fa)生(sheng)后,国(guo)药(yao)集(ji)团(tuan)党委号(hao)召集(ji)团(tuan)上下全(quan)员动员、全(quan)线(xian)出击、全(quan)域作战(zhan)、全(quan)力(li)以赴,全(quan)力(li)推进新冠疫苗(miao)(miao)研(yan)制工作。2020年(nian)1月(yue),国(guo)药(yao)集(ji)团(tuan)对疫苗(miao)(miao)研(yan)发(fa)作出部(bu)署,2月(yue)1日获(huo)科技(ji)部(bu)紧(jin)急立(li)项后,国(guo)药(yao)集(ji)团(tuan)中国(guo)生(sheng)物迅速组建多个科研(yan)团(tuan)队同步研(yan)发(fa),在诊断、治疗、预防三(san)条战(zhan)线(xian)全(quan)力(li)开(kai)展抗疫科技(ji)攻关,研(yan)发(fa)出核酸分子(zi)检测试剂;提(ti)出康复者恢(hui)复期(qi)血(xue)浆治疗技(ji)术并(bing)研(yan)发(fa)出新冠特(te)异性(xing)免疫球蛋白;研(yan)发(fa)出全(quan)球首(shou)个新冠灭活(huo)疫苗(miao)(miao),为(wei)疫情防控提(ti)供有力(li)支撑。
新(xin)冠(guan)(guan)疫(yi)(yi)苗(miao)科技攻关(guan)中(zhong)(zhong),国(guo)药集团(tuan)中(zhong)(zhong)国(guo)生(sheng)物(wu)独立自(zi)主(zhu)破解(jie)了(le)高(gao)等(deng)级(ji)(ji)生(sheng)物(wu)安(an)全(quan)条(tiao)件下(xia)大规模生(sheng)产灭活疫(yi)(yi)苗(miao)的一(yi)系列难题,攻克“卡脖(bo)子”技术,实(shi)现了(le)从(cong)千万(wan)剂(ji)级(ji)(ji)到数十(shi)亿(yi)剂(ji)级(ji)(ji)的跨越,源源不(bu)断制(zhi)造(zao)出(chu)新(xin)冠(guan)(guan)灭活疫(yi)(yi)苗(miao)支援全(quan)球抗(kang)疫(yi)(yi)。2020年12月30日,国(guo)药集团(tuan)中(zhong)(zhong)国(guo)生(sheng)物(wu)北京生(sheng)物(wu)制(zhi)品研究(jiu)所新(xin)冠(guan)(guan)灭活疫(yi)(yi)苗(miao)在中(zhong)(zhong)国(guo)获(huo)批附(fu)条(tiao)件上市(shi)。2021年2月25日,国(guo)药集团(tuan)中(zhong)(zhong)国(guo)生(sheng)物(wu)武汉生(sheng)物(wu)制(zhi)品研究(jiu)所新(xin)冠(guan)(guan)灭活疫(yi)(yi)苗(miao)获(huo)批附(fu)条(tiao)件上市(shi);4月9日,国(guo)药集团(tuan)中(zhong)(zhong)国(guo)生(sheng)物(wu)技术研究(jiu)院基因重组新(xin)冠(guan)(guan)疫(yi)(yi)苗(miao)获(huo)得临床(chuang)试验批件。
传(chuan)承百年积淀(dian) 打破常规研发
1919年(nian),我国(guo)(guo)最(zui)早(zao)从事(shi)传染病(bing)细菌学研(yan)究和生物制品生产(chan)(chan)的(de)机(ji)构——中(zhong)央防疫处成立,这(zhei)是国(guo)(guo)药集团(tuan)中(zhong)国(guo)(guo)生物的(de)前身(shen)。如今,国(guo)(guo)药集团(tuan)中(zhong)国(guo)(guo)生物已成为亚洲(zhou)产(chan)(chan)品最(zui)全(quan)、规模最(zui)大、综(zong)合(he)实力最(zui)强(qiang)的(de)生物医(yi)药企(qi)业(ye)之一(yi),年(nian)产(chan)(chan)疫苗(miao)50余种,在国(guo)(guo)家免疫规划全(quan)部15种疾病(bing)疫苗(miao)中(zhong),担(dan)负了超(chao)过80%的(de)供应任务,是我国(guo)(guo)生物制品行业(ye)的(de)领先(xian)企(qi)业(ye)。
针对此次新(xin)冠病毒(du)疫(yi)(yi)(yi)苗(miao)研(yan)(yan)发(fa)(fa),国(guo)药(yao)集团中(zhong)国(guo)生(sheng)(sheng)物敢于打破(po)常规(gui)。一是与时间赛(sai)跑,全(quan)面部署疫(yi)(yi)(yi)苗(miao)研(yan)(yan)发(fa)(fa)任务。仅98天就(jiu)进入(ru)临床试(shi)验(yan),177天投入(ru)紧急使(shi)用(yong),335天正(zheng)式上市,累计投入(ru)研(yan)(yan)发(fa)(fa)、临床、生(sheng)(sheng)产(chan)费用(yong)超(chao)过(guo)(guo)100亿元。二是从实际出发(fa)(fa),优选技术(shu)攻(gong)关路线。全(quan)面布(bu)局(ju)5条(tiao)技术(shu)路线,通过(guo)(guo)认真比选论(lun)证,考(kao)虑到灭活(huo)疫(yi)(yi)(yi)苗(miao)和基(ji)因重组疫(yi)(yi)(yi)苗(miao)技术(shu)成(cheng)熟、标准可控、保(bao)护效果(guo)好等,选择(ze)主攻(gong)灭活(huo)路线,并布(bu)局(ju)北京生(sheng)(sheng)物所(suo)、武汉生(sheng)(sheng)物所(suo)两(liang)个研(yan)(yan)究(jiu)所(suo)开展灭活(huo)疫(yi)(yi)(yi)苗(miao)研(yan)(yan)发(fa)(fa),同时,国(guo)药(yao)中(zhong)生(sheng)(sheng)研(yan)(yan)究(jiu)院基(ji)因重组疫(yi)(yi)(yi)苗(miao)快速推进,均(jun)取得(de)成(cheng)功。三是始(shi)终(zhong)坚持(chi)(chi)科学严谨规(gui)范的(de)要求。研(yan)(yan)发(fa)(fa)团队创造(zao)性地将流程(cheng)由过(guo)(guo)去的(de)串联(lian)(lian)改为(wei)并联(lian)(lian),大(da)大(da)加(jia)快研(yan)(yan)发(fa)(fa)速度,在研(yan)(yan)发(fa)(fa)过(guo)(guo)程(cheng)中(zhong),坚持(chi)(chi)“流程(cheng)不减(jian)、标准不变、数据(ju)不省”原则,制定科学规(gui)范的(de)研(yan)(yan)究(jiu)方案,接受严格(ge)的(de)监管(guan)要求和专业审(shen)议。四是持(chi)(chi)续技术(shu)提升,在传统灭活(huo)疫(yi)(yi)(yi)苗(miao)技术(shu)平(ping)台上,实现多项突破(po),取得(de)多个创新(xin)成(cheng)果(guo)。
坚持党(dang)建引领 提升(sheng)疫苗产能
为提升疫(yi)(yi)苗(miao)(miao)(miao)产能,推动疫(yi)(yi)苗(miao)(miao)(miao)大规(gui)模使(shi)用,国药集团(tuan)中(zhong)国生(sheng)物(wu)(wu)克服重重困难,在(zai)北京生(sheng)物(wu)(wu)所58天(tian)建(jian)(jian)成(cheng)(cheng)国内首个(ge)(ge)(ge)(ge)(ge)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3生(sheng)产车(che)间(jian)(jian)(jian),97天(tian)、98天(tian)分别建(jian)(jian)成(cheng)(cheng)第(di)(di)二个(ge)(ge)(ge)(ge)(ge)、第(di)(di)三(san)个(ge)(ge)(ge)(ge)(ge)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3生(sheng)产车(che)间(jian)(jian)(jian);在(zai)武(wu)汉生(sheng)物(wu)(wu)所,86天(tian)建(jian)(jian)成(cheng)(cheng)第(di)(di)一(yi)个(ge)(ge)(ge)(ge)(ge)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3实(shi)验(yan)(yan)室(shi)和(he)P3生(sheng)产车(che)间(jian)(jian)(jian)综合(he)体,76天(tian)建(jian)(jian)成(cheng)(cheng)第(di)(di)二个(ge)(ge)(ge)(ge)(ge)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3生(sheng)产车(che)间(jian)(jian)(jian);目前(qian)正在(zai)长春生(sheng)物(wu)(wu)所、兰(lan)州生(sheng)物(wu)(wu)所建(jian)(jian)设新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3实(shi)验(yan)(yan)室(shi)和(he)P3生(sheng)产车(che)间(jian)(jian)(jian)。与此同时,64天(tian)完成(cheng)(cheng)对(dui)国药集团(tuan)所属北京、武(wu)汉、长春、兰(lan)州、成(cheng)(cheng)都、上(shang)海6个(ge)(ge)(ge)(ge)(ge)生(sheng)物(wu)(wu)制品研究所的新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)配(pei)套(tao)生(sheng)产基地改造建(jian)(jian)设。另外,在(zai)阿联酋、塞尔维(wei)亚、阿根廷等国家(jia)的新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)灌(guan)装车(che)间(jian)(jian)(jian)正陆(lu)续(xu)投产。6月底,随(sui)着北京生(sheng)物(wu)(wu)所第(di)(di)三(san)个(ge)(ge)(ge)(ge)(ge)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)P3生(sheng)产车(che)间(jian)(jian)(jian)建(jian)(jian)成(cheng)(cheng)投产,国药集团(tuan)中(zhong)国生(sheng)物(wu)(wu)新(xin)(xin)冠(guan)病(bing)(bing)毒(du)(du)疫(yi)(yi)苗(miao)(miao)(miao)整体年产能超(chao)过50亿剂,成(cheng)(cheng)为目前(qian)全球最大新(xin)(xin)冠(guan)疫(yi)(yi)苗(miao)(miao)(miao)研发生(sheng)产基地和(he)供应商。
国药集团党(dang)委书记、董事长刘(liu)敬桢表示,国药集团勇担央企责(ze)任,坚(jian)持(chi)人(ren)民至上、生(sheng)命至上,在(zai)医药物资供(gong)应保障(zhang)、科研生(sheng)产(chan)、新冠病毒疫苗科技攻(gong)关和生(sheng)产(chan)供(gong)应等各条战(zhan)线全(quan)面出击(ji),取得一系列重(zhong)要(yao)战(zhan)略成果,护佑了人(ren)民生(sheng)命健康,捍卫(wei)了公共卫(wei)生(sheng)安(an)全(quan),未来,国药集团将进一步发挥中国新冠病毒疫苗作为全(quan)球公共产(chan)品的(de)重(zhong)要(yao)作用,造(zao)福国人(ren),为全(quan)球抗(kang)疫贡献(xian)力量。
数据来源:国药集团